Dr. Crown on the Role of Eribulin Mesylate in TNBC

Publication
Video
Supplements and Featured PublicationsThe Role of Chemotherapy and Novel Combinations in Triple Negative Breast Cancer
Volume 1
Issue 1

John Crown, BCh, BAO, BSc, MD, MBA, discusses the role of eribulin mesylate in triple-negative breast cancer.

John Crown, BCh, BAO, BSc, MD, MBA, professor and consultant, medical oncology, St. Vincent’s Private Hospital, Dublin, Ireland, discusses the role of eribulin mesylate (Halaven) in triple-negative breast cancer.

Multiple randomized trials have established eribulin as an active treatment for patients with TNBC, Crown says.

Moreover, the drug provides an overall survival (OS) benefit compared with standard chemotherapy for heavily pretreated patients with metastatic disease, explains Crown.

Notably, findings from a subgroup analysis of a phase 3 trial demonstrated superior OS with eribulin compared with capecitabine (Xeloda) among patients with HER2-negative tumors, including HER2-negative breast cancer and TNBC, Crown says.

As such, eribulin appears to have established itself as a potent agent in the TNBC armamentarium, concludes Crown.

Related Videos
Nidia Zapata, MD
Nidia Zapata, MD
Arndt Vogel, MD
Nicole Rich, MD
Ivan Marazzi, PhD, an associate professor at Mount Sinai,
Kelly de Ligt, PhD
Chau T. Dang, MD
Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.
Paz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.
Michele Ghidini, MD, PhD